Celldex Therapeutics (CLDX) vs Lantheus (LNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 93.2% versus a gain of 16.1%. Over five years, LNTH leads with a +330.7% price change compared with -34.1% for CLDX. Lantheus is the larger company by market cap ($6.54 billion vs $2.39 billion), about 2.7 times the size.
Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -16748.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | LNTH |
|---|---|---|
| Share price | $30.43 | $100.18 |
| Market cap | $2.39B | $6.54B |
| 1-day change | -1.85% | +0.23% |
| YTD return | +12.04% | +50.53% |
| 1-year return | +16.06% | +93.25% |
| 5-year return | -34.11% | +330.70% |
| P/E ratio (TTM) | — | 24.26 |
| Forward P/E | — | 15.71 |
| EPS (TTM) | $-4.27 | $4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | $1.54B |
| Revenue growth (YoY) | -77.99% | +0.50% |
| Net income (latest FY) | $-258.76M | $233.56M |
| Gross margin | 87.06% | 61.10% |
| Operating margin | -18599.81% | 20.16% |
| Net margin | -16748.03% | 15.15% |
| 52-week high | $45.14 | $111.86 |
| 52-week low | $22.10 | $50.16 |
| Distance from 52-week high | -32.59% | -10.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +107.26% | +7.55% |
| Average volume | 1.26M | 1.34M |
| Shares outstanding | 78.53M | 65.30M |
| Employees | 198 | 1,193 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 2.7 times larger than Celldex Therapeutics by market value ($6.54B vs $2.39B).
- LNTH has outperformed CLDX by 77.2 percentage points over the past year.
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -16748.0 cents for Celldex Therapeutics.
- Lantheus grew revenue faster in its latest fiscal year (+0.50% vs -77.99%).
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
CLDX vs LNTH FAQ
Which is bigger, Celldex Therapeutics or Lantheus?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $2.39B for Celldex Therapeutics (CLDX).
Which stock has performed better over the past year, CLDX or LNTH?
LNTH returned +93.25% over the past 12 months, compared with +16.06% for CLDX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Lantheus in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.